Allurion TechnologiesALURD -2.11%16 Days Payable is 176.15 as of Mar. 2026, which is 29% below its 10-year median of 246.81. GuruFocus rates ALURD with a GF Score™ of 16/100 and a GF Value™ of $10.66 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 795 Medical Devices & Instruments companies, Allurion Technologies ranks better than 86.29% on this metric.
The historical rank and industry rank for Allurion Technologies's Days Payable or its related term are showing as below:
ALURD'
s Days Payable Range Over the Past 10 Years
Min: 65.24 Med: 246.81 Max: 327.01
Current: 223.56
During the past 5 years, Allurion Technologies's highest Days Payable was 327.01. The lowest was 65.24. And the median was 246.81.
ALURD's Days Payable is ranked better than 86.29% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 67.87
vs ALURD: 223.56
Allurion Technologies Days Payable Historical Data
* Premium members only.
The historical data trend for Allurion Technologies's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ALURD vs ALRTF, VVOS, SINT: Days Payable Comparison
For the Medical Devices subindustry, Allurion Technologies's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Allurion Technologies Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Allurion Technologies's Days Payable distribution charts can be found below:
* The bar in red indicates where Allurion Technologies's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Allurion Technologies's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Allurion Technologies (ALURD) has a Days Payable of 176.15 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Allurion Technologies and its competitors. This is 29% below median its historical median of 246.81. Over the past decade, Allurion Technologies' Days Payable has ranged from 65.24 to 327.01. According to the industry distribution chart, Allurion Technologies ranks #109 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 13.7%.
Is Allurion Technologies' Days Payable too high?
Allurion Technologies' current Days Payable of 176.15 is 29% below median its 10-year median of 246.81. Over the past 10 years, this metric has ranged from a low of 65.24 to a high of 327.01. The Medical Devices & Instruments industry median Days Payable is 67.87. Allurion Technologies' value of 176.15 is 159.5% above this industry median. Based on the distribution chart, Allurion Technologies ranks #109 out of 795 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Allurion Technologies has a GF Score™ of 16/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Allurion Technologies' Days Payable compare to ALRTF and VVOS?
According to the Medical Devices & Instruments industry distribution chart, Allurion Technologies ranks #109 out of 795 companies for Days Payable. This places Allurion Technologies in the top 14% of its industry — outperforming the majority of peers. The industry median Days Payable is 67.87. Allurion Technologies' value of 176.15 is 159.5% above this benchmark. Historically, Allurion Technologies' own Days Payable has ranged from 65.24 to 327.01 over the past decade. While the company's 10-year median is 246.81 vs. the industry median of 67.87, Allurion Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 67.87, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Allurion Technologies's current Days Payable of 176.15 is 159.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Allurion Technologies and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 67.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Allurion Technologies's current Days Payable is 176.15, which is 29% below median its own 10-year median of 246.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allurion Technologies stock overvalued right now?
Based on GuruFocus' analysis, Allurion Technologies (ALURD) is currently considered Possible Value Trap. The stock's GF Value™ is $10.66, compared to a current price of $5.91 — trading 44.6% below its estimated fair value. The current Days Payable is 176.15, which is 29% below median its 10-year median of 246.81 and 159.5% above the Medical Devices & Instruments industry median of 67.87. Allurion Technologies' overall GF Score™ is 16/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Allurion Technologies (ALURD), the current Days Payable is 176.15 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Allurion Technologies (ALURD) Overvalued in 2026?
Based on GuruFocus' analysis, Allurion Technologies stock appears to be undervalued.
The current stock price of $5.91 is trading 44.6% below its estimated GF Value™ of $10.66.
GuruFocus considers Allurion Technologies to be Possible Value Trap.
Key valuation signals for ALURD:
Days Payable: 176.15 (29% below median its 10-year median of 246.81)
GF Value™: $10.66 vs. price of $5.91 (44.6% below fair value)
Industry Position: 159.5% above the Medical Devices & Instruments median (#109 of 795)
No single metric tells the full story. See the ALURD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.
16GF Score
Get the complete analysis for ALURD
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALURD has been successfully added to your 
